RT Journal Article
SR Electronic
T1 The Report on China-Spain Joint Clinical Testing for Rapid COVID-19 Risk Screening by Eye-region Manifestations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.24.21263766
DO 10.1101/2021.09.24.21263766
A1 Fu, Yanwei
A1 Li, Feng
A1 Fustel, Paula boned
A1 Zhao, Lei
A1 Jia, Lijie
A1 Zheng, Haojie
A1 Sun, Qiang
A1 Rong, Shisong
A1 Tang, Haicheng
A1 Xue, Xiangyang
A1 Yang, Li
A1 Li, Hong
A1 Xie, Jiao
A1 Wang, Wenxuan
A1 Li, Yuan
A1 Wang, Wei
A1 Pei, Yantao
A1 Wang, Jianmin
A1 Wu, Xiuqi
A1 Zheng, Yanhua
A1 Tian, Hongxia
A1 Gu, Mengwei
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.24.21263766.abstract
AB Background The worldwide surge in coronavirus cases has led to the COVID-19 testing demand surge. Rapid, accurate, and cost-effective COVID-19 screening tests working at a population level are in imperative demand globally.Methods Based on the eye symptoms of COVID-19, we developed and tested a COVID-19 rapid prescreening model using the eye-region images captured in China and Spain with cellphone cameras. The convolutional neural networks (CNNs)-based model was trained on these eye images to complete binary classification task of identifying the COVID-19 cases. The performance was measured using area under receiver-operating-characteristic curve (AUC), sensitivity, specificity, accuracy, and F1. The application programming interface was open access.Findings The multicenter study included 2436 pictures corresponding to 657 subjects (155 COVID-19 infection, 23·6%) in development dataset (train and validation) and 2138 pictures corresponding to 478 subjects (64 COVID-19 infections, 13·4%) in test dataset. The image-level performance of COVID-19 prescreening model in the China-Spain multicenter study achieved an AUC of 0·913 (95% CI, 0·898-0·927), with a sensitivity of 0·695 (95% CI, 0·643-0·748), a specificity of 0·904 (95% CI, 0·891 -0·919), an accuracy of 0·875(0·861-0·889), and a F1 of 0·611(0·568-0·655).Interpretation The CNN-based model for COVID-19 rapid prescreening has reliable specificity and sensitivity. This system provides a low-cost, fully self-performed, non-invasive, real-time feedback solution for continuous surveillance and large-scale rapid prescreening for COVID-19.Funding This project is supported by Aimomics (Shanghai) IntelligentCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNot publicly available due to NDA & AIMOMICS license protectionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Shanghai Public Health Clinical Center, Fudan University (approval No.: YJ-2020-S078-02), the fifth hospital of Shijiazhuang affiliated to Hebei Medical University (approval No.: 2021005), and the Ethics Committee on Drug Research of the University and Polytechnic Hospital La Fe (registry No: 2020-637-1). Informed consents were obtained from all participating individuals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot publicly available due to NDA & AIMOMICS license protection